Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9099027 | 0.77 | PTPN2 (0.44) | PTPN2PTPRBPTPN6PTK2MAPK8 | |
| SCHEMBL5049650 | 0.77 | PKM (0.45) | PTPN2PTPRBPTPN6PTK2MAPK8 | |
| SCHEMBL13270043 | 0.76 | PTK2 (0.71) | PTK2MAPK8ALDH1A1MAPTMEN1 | |
| SCHEMBL1008847 | 0.75 | PTPN2 (0.43) | PTPN2PTPRBPTPN6PTK2MAPK8 | |
| SCHEMBL13764835 | 0.75 | PTPN2 (0.72) | PTPN2PTPRBPTPN6PTK2MAPK8 | |
| SCHEMBL1009157 | 0.75 | PTPN2 (0.43) | PTPN2PTPRBPTPN6PTK2MAPK8 | |
| SCHEMBL10404671 | 0.74 | HDAC1 (0.51) | PTK2MAPK8ALDH1A1MEN1MAPK1 | |
| SCHEMBL7673864 | 0.72 | PTPN2 (0.44) | PTPN2PTPRBPTPN6PTK2MAPK8 | |
| SCHEMBL2948840 | 0.71 | MEN1 (0.50) | PTPN2PTPRBPTPN6MAPK8ALDH1A1 | |
| SCHEMBL3510937 | 0.71 | SMN1; SMN2 (0.61) | ALDH1A1MAPTMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3012328-B1 | METHODS FOR DETECTING ONCOGENIC MUTATIONS | SYSMEX CORP (JP) | 2019-04-10 | — | — | EP | disclosed |
| US-9845507-B2 | Methods for detecting oncogenic mutations | SYSMEX CORPORATION (JP) | 2017-12-19 | — | — | US | disclosed |
| EP-3012328-A2 | METHODS FOR DETECTING ONCOGENIC MUTATIONS | SYSMEX CORPORATION (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-20160090632-A1 | METHODS FOR DETECTING ONCOGENIC MUTATIONS | SYSMEX CORPORATION (JP) | 2016-03-31 | — | — | US | disclosed |
| EP-2227254-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI Pharmaceuticals, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073139-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090136517-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI PHARMACEUTICALS, INC. | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136517-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | KIT, EGFR, AURKC | PTPN2 1419/4885PTPRB 1205/4885PTPN6 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.